Literature DB >> 33811

Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man.

O Rönn, C Graffner, G Johnsson, L Jordö, P Lundborg, J Wikstrand.   

Abstract

The haemodynamic effects of the selective beta1-adrenoceptor agonist prenalterol were studied in healthy subjects before and after therapeutic doses of the selective beta1-adrenoceptor blocker metoprolol. Plasma levels of the drugs were also determined in order to calculate certain pharmacokinetic variables. Intravenous infusion of prenalterol 0.13, 0.25 and 0.50 mg induced a dose-dependent decrease in total electromechanical systole (QA2) and pre-ejection period (PEP). The effect on left ventricular ejection time (LVET) was not significant. Increases in systolic blood pressure and heart rate were dose-dependent. Diastolic blood pressure did not change significantly. When metoprolol had been administered in a cumulative dose of 150 mg (mean maximal plasma level, 284 nmol/l) prenalterol had to be administered in doses that were twelve times higher than before the beta-blocker in order to induce the same haemodynamic effects. Prenalterol was rapidly distributed with an average half life of 8 min. This indicates that distribution equilibrium will be achieved within 30 min after intravenous administration. The overall elimination rate in the post-distributive phase corresponded to an average half life of 2.0 h.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 33811     DOI: 10.1007/bf00563552

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Quantitative determination of metoprolol in plasma and urine by gas chromatography.

Authors:  M Ervik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

4.  Human pharmacology studies with a new, orally active stimulant of cardiac adrenergic beta-receptors.

Authors:  M Knaus; B Pfister; U C Dubach; P R Imhof
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

5.  Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62.

Authors:  G Johnsson; L Jordö; P Lundborg; O Rönn; I Welin-Fogelberg; J Wikstrand
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

6.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

7.  Bedside technics for the evaluation of ventricular function in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

8.  Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.

Authors:  R R Tuttle; J Mills
Journal:  Circ Res       Date:  1975-01       Impact factor: 17.367

9.  Value of systolic and diastolic time intervals. Studies in normotensive and hypertensive 50-year-old men and in patients after myocardial infarction.

Authors:  J Wikstrand; G Berglund; L Wilhelmsen; I Wallentin
Journal:  Br Heart J       Date:  1978-03
  9 in total
  19 in total

1.  The lack of a pronounced preference of prenalterol for the beta-l-adrenoceptor subtype.

Authors:  N Rohm; J Wagner; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

2.  Effects of a beta 1-selective adrenergic agonist in normal human volunteers.

Authors:  K A Meurer; R Lang; V Hombach; A Helber
Journal:  Klin Wochenschr       Date:  1980-04-15

3.  Haemodynamic effects, plasma concentrations and tolerance of orally administered prenalterol in man.

Authors:  A Weiss; B Pfister; P Imhof; P H Degen; D Burckhardt; U C Dubach
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

4.  Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.

Authors:  U Dahlström; C Graffner; U Jonsson; K J Hoffmann; E Karlsson; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Haemodynamic effects of a new beta 1-receptor agonist in acute myocardial infarction. A useful antidote to unwanted cardiac effects of beta-blocking agents.

Authors:  R Ariniego; F Waagstein; B Mombay; A Hjalmarson
Journal:  Br Heart J       Date:  1979-08

6.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Cardiostimulatory effects of prenalterol, a beta-1 adrenoceptor partial agonist, in vivo and in vitro. Correlation between physiological effects and adenylate cyclase activity.

Authors:  A Hedberg; E Carlsson; E Fellenius; B Lundgren
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

8.  Pharmacokinetic studies in man of the selective beta 1-adrenoceptor agonist, prenalterol.

Authors:  C Graffner; K J Hoffmann; G Johnsson; P Lundborg; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Ventilatory and haemodynamic effects of prenalterol and terbutaline in asthmatic patients.

Authors:  A P Greefhorst; C L van Herwaarden
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.

Authors:  H Mattsson; T Andersson; E Carlsson; A Hedberg; B Lundgren; T Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.